These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 14734599)

  • 1. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.
    Schapira AH; Olanow CW
    JAMA; 2004 Jan; 291(3):358-64. PubMed ID: 14734599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the effects of therapy in Parkinson disease.
    Shults CW; Haas R; Oakes D; Kieburtz K; Plumb S; Shoulson I; Beal MF; Juncos J; Nutt J
    JAMA; 2004 May; 291(20):2430-1; author reply 2431. PubMed ID: 15161889
    [No Abstract]   [Full Text] [Related]  

  • 3. ALS lessons learned from other neurological diseases. Parkinson's disease.
    Fahn S
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():26-30. PubMed ID: 15512865
    [No Abstract]   [Full Text] [Related]  

  • 4. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH
    Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Olanow CW; Jankovic J
    Mov Disord; 2005; 20 Suppl 11():S3-10. PubMed ID: 15822111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targets for neuroprotection in Parkinson's disease.
    Yacoubian TA; Standaert DG
    Biochim Biophys Acta; 2009 Jul; 1792(7):676-87. PubMed ID: 18930814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies.
    Herrero MT; Pagonabarraga J; Linazasoro G
    Neurologist; 2011 Nov; 17(6 Suppl 1):S54-66. PubMed ID: 22045327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early pharmacologic treatment in Parkinson's disease.
    Hauser RA
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists and neuroprotection in Parkinson's disease.
    Olanow CW; Jenner P; Brooks D
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease.
    Clarke CE
    Lancet Neurol; 2004 Aug; 3(8):466-74. PubMed ID: 15261607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of early Parkinson's disease.
    Koller WC
    Neurology; 2002 Feb; 58(4 Suppl 1):S79-86. PubMed ID: 11909989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.